ImmunityBio, Inc. Stock Prediction and Forecast [IBRX]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 24 Jan 2026, 03:56 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for ImmunityBio, Inc. Stock Prediction and Forecast [IBRX]](https://i.ytimg.com/vi/QoCtVMNFCAo/hqdefault.jpg)
AI-generated source summary
The stock IBRX is showing a strong bullish trend based on technical indicators. The 50-day moving average is at $167.08 and the 200-day moving average is at $152.36, with the current price above both, signaling bullishness. Volume at the last close was 99.01 million, higher than average, indicating increased investor interest. Fundamental analysis shows earnings per share at $5.89 and a P/E ratio of 30.09, suggesting consistent growth and a fair valuation. The stock experienced significant volatility, with a 52-week low of $124.17 and a high of $179.35. The stock is currently trading at $6.46, with a target of $7.37, and a fail bound at $6.37. A breach below $6.37 would invalidate the bullish short-term outlook. The long-term forecast suggests a potential change of -5.5% to 5.51% over the next 12 months. The stock has shown resilience, with a buy signal from the 3-month MACD. However, some negative signals from pivot points suggest potential near-term volatility.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.